- Home
- Companies
- Beta Lifescience
- Articles
Beta Lifescience articles
Tumors and Blood Vessel Growth
Tumor, as an abnormal mass of cells, has blood vessels of various sizes that can be seen everywhere on the surface and deep within it. Nutrients for life are continuously supplied to the depths of tumor cells through these blood vessels. As the tumor continues to grow, nearby blood vessels also undergo rapid and chaotic growth, with these newly formed capillaries appearing disorganized, much like the tumor itself.
The biologics license application (BLA) has been accepted for Enfortumab Vedotin for the treatment of locally advanced or metastatic urothelial carcinoma in patients who have previously received PD-1/PD-L1 inhibitors and platinum-containing chemotherapy. Enfortumab Vedotin is the first domestically submitted targeted antibody-drug conjugate that specifically targets Nectin-4.
Enfortumab vedotin-ejfv (PADCEV®) is a first-in-class antibody-drug conjugate (ADC) that targets Nect
Thymic Stromal Lymphopoietin (TSLP) is a multifunctional cytokine that acts on various cell types, including dendritic cells, T cells, B cells, neutrophils, mast cells, eosinophils, and innate lymphoid cells, affecting their maturation, survival, and recruitment. It is well-known for its role in promoting type 2 immune responses, such as allergic diseases. In 2021, a monoclonal antibody targeting TSLP was approved for the treatment of severe asthma.
TSLP and TSLPR
Introduction to IL-36 Family
Twenty years ago, Interleukin 36 (IL-36) was discovered as a member of the IL-1 superfamily. Its gene is located on chromosome 2 in an IL gene cluster, including IL1A - IL1B - IL37 - IL36G - IL36A - IL36B - IL36RN - IL38 - IL1RN, with IL-36 encoding genes transcribed far away from the centromere.
There are four known subtypes of IL-36, which have been renamed multiple times and were formerly known as IL-1F6, IL-1F8, IL-1F9, and IL-1F5.
Autoimmune disease target - IL-17 Family
IL-17 plays an important role in promoting autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis (AS). Currently, five large-molecule biopharmaceuticals targeting IL-17/IL-17R are available worldwide, including four IL-17 monoclonal antibodies and one IL-17RA monoclonal antibody, namely Secukinumab(Novartis), Ixekizumab(Eli Lilly), Netakimab(Biocad), Brodalumab(Kyowa Hakko Kirin), and Bimekizumab(U